Metabolic parameters predict survival and toxicity in chimeric antigen receptor T‐cell therapy‐treated relapsed/refractory large B‐cell lymphoma

Prognostic value of FDG‐PET/CT response for patient selection before chimeric antigen receptor‐T‐cells therapy in non‐Hodgkin lymphoma

(2022) Clément Bailly et al.   HEMATOLOGICAL ONCOLOGY

Prognostic Value of Radiomic Features of 18F-FDG PET/CT in Patients With B-Cell Lymphoma Treated With CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T Cells

(2022) Yeye Zhou et al.   Frontiers in Oncology

Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index

(2022) N. George Mikhaeel et al.   JOURNAL OF CLINICAL ONCOLOGY

Assessing the Role of Radiotherapy in Patients with Refractory or Relapsed High-Grade B-Cell Lymphomas Treated with CAR T-Cell Therapy

(2022) Hazim S. Ababneh et al.   RADIOTHERAPY AND ONCOLOGY

Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells

(2021) Pierre Sesques et al.   CLINICAL NUCLEAR MEDICINE

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

(2021) Frederick L. Locke et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma

(2021) Andrea Kuhnl et al.   Blood Advances

High total metabolic tumor volume at baseline allows discrimination of survival even in patients aged 60 to 80 years responding to R-CHOP

(2020) Laetitia Vercellino et al.   BLOOD

Bridging Radiation Therapy Prior to Commercial Chimeric Antigen Receptor T-Cell Therapy for relapsed/refractory aggressive B-cell lymphoma

(2020) Christopher M. Wright et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma

(2020) Erin A. Dean et al.   Blood Advances

Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

(2020) Frederick L. Locke et al.   Blood Advances

Baseline Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT Predict Outcomes in T-Cell Lymphoblastic Lymphoma

(2020) Xiaoyan Feng et al.   Cancer Research and Treatment

Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: A meta-analysis

(2019) Baoping Guo et al.   PLoS One

Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy in Patients with Non-Hodgkin Lymphoma

(2019) Jiasheng Wang et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial

(2019) Christine Schmitz et al.   EUROPEAN JOURNAL OF CANCER

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients

(2017) Anne-Ségolène Cottereau et al.   JOURNAL OF NUCLEAR MEDICINE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Baseline Metabolic Tumor Volume Predicts Outcome in High–Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies

(2016) Michel Meignan et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma

(2016) Mingge Zhou et al.   Oncotarget

Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma

(2012) Tae Min Kim et al.   CANCER